AACR 2022 | A novel subcutaneous CAR-T therapy for the treatment of hematological malignancies
Sid P. Kerkar
• 11 Apr 2022
Sid P. Kerkar, MD, Exuma Biotech, West Palm Beach, FL, gives an overview of a novel subcutaneous chimeric antigen receptor T-cell (CAR-T) therapy consisting of both T-cell and natural killer (NK) features. Dr Kerkar briefly summarizes the underlying biology of this novel CAR-T treatment, as well as the short manufacturing period required for these cells. Dr Kerkar then highlights some benefits of this novel approach, including improved cell expansion and effective tumor clearing abilities. This interview took place at the American Association for Cancer Research Annual Meeting in New Orleans, LA.
Disclosures
VP of R&D at Exuma Biotech
